Oculis begins treating first patient in PIONEER-1 trial
FDA granted Special Protocol Assessment for Privosegtor. This follows positive Phase 2 ACUITY data towards a first-in-class optic neuritis treatment.
Latest Oculis News & Updates
See the latest news and media coverage for Oculis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical biopharmaceutical company
oculis.com- Headquarters
- Lausanne, Switzerland
- Founded year
- 2017
- Company type
- Public company
- Number of employees
- 70–200
- Industry
- Pharmaceuticals
Last updated
Latest news about Oculis
In short: Oculis shifted its focus to neuro-ophthalmology following a Phase 3 trial failure, while advancing its Privosegtor and Licaminlimab assets.
Company announcements
Oculis acquires Privosegtor assets from Accure Therapeutics
The transaction includes a $3.8 million upfront payment and share consideration, strengthening Oculis' neuro-ophthalmology pipeline ahead of Phase 3 trials
Oculis reports Q2 2026 financial results and updates pipeline progress
Cash reserves reach $282.3 million as Privosegtor enters Phase 3 trials while Licaminlimab enrollment exceeds 45%. The company pivots to neuro-ophthalmology with strong balance sheet support.
Oculis receives positive FDA feedback for Privosegtor
The FDA supports the regulatory pathway for treating acute multiple sclerosis relapses with Privosegtor. Oculis plans to submit a new Investigational New Drug application in Q4 2026.
Media coverage
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS...
Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Oculis acquires development and commercial rights to Privosegtor
Biotech company Oculis will acquire all worldwide development and commercial rights to Privosegtor, one of its two core product candidates, from Accure. This acquisition will...
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%,...
Never miss news about Oculis
Track Oculis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Oculis competitors & trending companies
Browse news for competitors to Oculis and other trending companies.
Kalaris
Aura Biosciences
Annexin Pharmaceuticals
Active Biotech
Outlook Therapeutics
Ticketplus
HELP Therapeutics
CMC
ManpowerGroup
Arcosa
Alliance Entertainment
QXO
Reliant Stones
Amber
The Pool Tile Co
Cinajus
Armstone
Eco Outdoor
Sareen Stone
Stone Planet
Salience Labs
Trio Petroleum
Arianespace
American Eagle
AEO
OLB
Compass
MAQS
Roschier
Möller & Partners
Normain
Incentive Industrier
Pinecone
SSHL